{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:42:35Z","timestamp":1777552955724,"version":"3.51.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001353","name":"National Kidney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>We aimed to determine the prevalence of antibodies against angiotensin II type 1 receptor (AT1RAb) in hypertensive adults and elucidate the relation of antihypertensive medication type to blood pressure (BP) among persons with and without AT1RAb.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Sera from participants in the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study with hypertension were tested for AT1RAb using a commercial Enzyme-linked immunosorbent assay (ELISA) (One Lambda; positive \u226517 units\/ml). BP measurements, uncontrolled BP (systolic BP \u2265140 and\/or diastolic BP \u226590 mm Hg), and effect of BP medication type were compared for AT1RAb positive (+) vs. negative (\u2212) participants using descriptive statistics and multivariable regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>One hundred and thirty-two (13.1%) participants were AT1RAb+. Compared with AT1RAb\u2212, AT1RAb+ persons were more likely to be white (47% vs. 36.7%; P = 0.03) but had similar comorbid disease burden. In models adjusting for age, sex, and race, AT1RAb+ persons had higher diastolic BP (\u03b2 = 2.61 mm Hg; SE = 1.03; P = 0.01) compared with AT1RAb\u2212 participants. Rates of uncontrolled BP were similar between the groups. AT1RAb+ persons on an angiotensin receptor blocker (ARB; n = 21) had a mean of 10.5 mm Hg higher systolic BP (SE = 4.56; P = 0.02) compared with AT1RAb+ persons using other BP medications. The odds of uncontrolled BP among AT1RAb+ participants on an ARB was 2.05 times that of those on other medications. AT1RAb\u2212 persons prescribed an angiotensin-converting enzyme inhibitor (ACEi) had 1.8 mm Hg lower diastolic BP (SE = 0.81; P = 0.03) than AT1RAb\u2212 persons not prescribed an ACEi.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>AT1RAb was prevalent among hypertensive adults and was associated with higher BP among persons on an ARB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpaa071","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T19:09:51Z","timestamp":1587496191000},"page":"734-740","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence of Angiotensin II Type 1 Receptor Antibodies in Persons With Hypertension and Relation to Blood Pressure and Medication"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-9113","authenticated-orcid":false,"given":"Mary Carmelle","family":"Philogene","sequence":"first","affiliation":[{"name":"Division of Immunogenetics, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingfen","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions , Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flor","family":"Alvarado","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions , Baltimore, Maryland, USA"},{"name":"Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal S","family":"Fedarko","sequence":"additional","affiliation":[{"name":"Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan B","family":"Zonderman","sequence":"additional","affiliation":[{"name":"National Institute on Aging, National Institutes of Health , Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele K","family":"Evans","sequence":"additional","affiliation":[{"name":"National Institute on Aging, National Institutes of Health , Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deidra C","family":"Crews","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions , Baltimore, Maryland, USA"},{"name":"Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"2022100616085110900_CIT0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18553\/jmcp.2007.13.s8-b.9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"2022100616085110900_CIT0002","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"2022100616085110900_CIT0003","first-page":"341","article-title":"Managing hypertension using combination therapy","volume":"101","author":"Smith","year":"2020","journal-title":"Am Fam Physician"},{"key":"2022100616085110900_CIT0004","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.compchemeng.2018.02.009","article-title":"Modeling sex differences in the renin angiotensin system and the efficacy of antihypertensive therapies","volume":"112","author":"Leete","year":"2018","journal-title":"Comput Chem Eng"},{"key":"2022100616085110900_CIT0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/clpt.2008.101","article-title":"Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans","volume":"84","author":"Schelleman","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"2022100616085110900_CIT0006","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.tpj.6500493","article-title":"Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke","volume":"8","author":"Schelleman","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"2022100616085110900_CIT0007","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2217\/14622416.9.9.1331","article-title":"Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics","volume":"9","author":"Schelleman","year":"2008","journal-title":"Pharmacogenomics"},{"key":"2022100616085110900_CIT0008","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcjd.2017.09.011","article-title":"The divergent cardiovascular effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in adult patients with type 2 diabetes mellitus","volume":"42","author":"Strauss","year":"2018","journal-title":"Can J Diabetes"},{"key":"2022100616085110900_CIT0009","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/10641963.2018.1529781","article-title":"Angiotensin II type 1 receptor blockers prevent aortic arterial stiffness in elderly patients with hypertension","volume":"41","author":"Zhu","year":"2019","journal-title":"Clin Exp Hypertens"},{"key":"2022100616085110900_CIT0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.yexcr.2017.08.030","article-title":"Inhibition of angiotension II type 1 receptor reduced human endothelial inflammation induced by low shear stress","volume":"360","author":"Chao","year":"2017","journal-title":"Exp Cell Res"},{"key":"2022100616085110900_CIT0011","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.109.137935","article-title":"Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1","volume":"54","author":"LaMarca","year":"2009","journal-title":"Hypertension"},{"key":"2022100616085110900_CIT0012","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11906-019-0971-6","article-title":"Adaptive immunity in hypertension","volume":"21","author":"Mikolajczyk","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"2022100616085110900_CIT0013","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1139\/y02-160","article-title":"Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia","volume":"81","author":"Wallukat","year":"2003","journal-title":"Can J Physiol Pharmacol"},{"key":"2022100616085110900_CIT0014","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/ndt\/gfm072","article-title":"Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology","volume":"22","author":"Dragun","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2022100616085110900_CIT0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1172\/JCI4106","article-title":"Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor","volume":"103","author":"Wallukat","year":"1999","journal-title":"J Clin Invest"},{"key":"2022100616085110900_CIT0016","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1681\/ASN.2018080868","article-title":"Early acute microvascular kidney transplant rejection in the absence of anti-HLA antibodies is associated with preformed IgG antibodies against diverse glomerular endothelial cell antigens","volume":"30","author":"Delville","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2022100616085110900_CIT0017","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/ajt.15564","article-title":"Hyperacute graft dysfunction in an orthotopic heart transplant in the presence of non-HLA antibodies","volume":"20","author":"Villa","year":"2020","journal-title":"Am J Transplant"},{"key":"2022100616085110900_CIT0018","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.humimm.2019.04.012","article-title":"Antibodies against angiotensin II Type 1 and endothelin a receptors: relevance and pathogenicity","volume":"80","author":"Philogene","year":"2019","journal-title":"Hum Immunol"},{"key":"2022100616085110900_CIT0019","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.humimm.2016.08.009","article-title":"Angiotensin II type-1 receptor antibody (AT1Rab) associated humoral rejection and the effect of peri operative plasma exchange and candesartan","volume":"77","author":"Carroll","year":"2016","journal-title":"Hum Immunol"},{"key":"2022100616085110900_CIT0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJMoa035717","article-title":"Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection","volume":"352","author":"Dragun","year":"2005","journal-title":"N Engl J Med"},{"key":"2022100616085110900_CIT0021","first-page":"267","article-title":"Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS): overcoming barriers to implementing a longitudinal, epidemiologic, urban study of health, race, and socioeconomic status","volume":"20","author":"Evans","year":"2010","journal-title":"Ethn Dis"},{"key":"2022100616085110900_CIT0022","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/TP.0000000000001231","article-title":"Anti-angiotensin II type 1 receptor and anti-endothelial cell antibodies: a cross-sectional analysis of pathological findings in allograft biopsies","volume":"101","author":"Philogene","year":"2017","journal-title":"Transplantation"},{"key":"2022100616085110900_CIT0023","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"2022100616085110900_CIT0024","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCULATIONAHA.116.022385","article-title":"Discovery and validation of agonistic angiotensin receptor autoantibodies as biomarkers of adverse outcomes","volume":"135","author":"Abadir","year":"2017","journal-title":"Circulation"},{"key":"2022100616085110900_CIT0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.kint.2017.06.034","article-title":"Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation","volume":"93","author":"Pearl","year":"2018","journal-title":"Kidney Int"},{"key":"2022100616085110900_CIT0026","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ekir.2018.12.011","article-title":"Cytokine profiles associated with angiotensin II type 1 receptor antibodies","volume":"4","author":"Pearl","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2022100616085110900_CIT0027","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3390\/ijms17050684","article-title":"12-Lipoxygenase inhibition on microalbuminuria in type-1 and type-2 diabetes is associated with changes of glomerular angiotensin II type 1 receptor related to insulin resistance","volume":"17","author":"Xu","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2022100616085110900_CIT0028","first-page":"343","article-title":"[Angiotensin II type 1 receptor autoantibody induces myocardial fibrosis by activating cardiac fibroblasts]","volume":"70","author":"Hao","year":"2018","journal-title":"Sheng Li Xue Bao"},{"key":"2022100616085110900_CIT0029","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12889-016-2945-9","article-title":"Cross-sectional relations of race and poverty status to cardiovascular risk factors in the Healthy Aging in Neighborhoods of Diversity across the Lifespan (HANDLS) study","volume":"16","author":"Waldstein","year":"2016","journal-title":"BMC Public Health"},{"key":"2022100616085110900_CIT0030","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cell.2015.04.011","article-title":"Structure of the Angiotensin receptor revealed by serial femtosecond crystallography","volume":"161","author":"Zhang","year":"2015","journal-title":"Cell"},{"key":"2022100616085110900_CIT0031","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar4503","article-title":"Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients","volume":"16","author":"G\u00fcnther","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2022100616085110900_CIT0032","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/mol.115.099176","article-title":"Structure-function basis of attenuated inverse agonism of angiotensin II type 1 receptor blockers for active-state angiotensin II type 1 receptor","volume":"88","author":"Takezako","year":"2015","journal-title":"Mol Pharmacol"},{"key":"2022100616085110900_CIT0033","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1210\/jc.2013-3282","article-title":"Autoimmune mechanisms activating the angiotensin AT1 receptor in \u2018primary\u2019 aldosteronism","volume":"99","author":"Kem","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022100616085110900_CIT0034","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.phrs.2017.06.013","article-title":"Current topics in angiotensin II type 1 receptor research: focus on inverse agonism, receptor dimerization and biased agonism","volume":"123","author":"Takezako","year":"2017","journal-title":"Pharmacol Res"},{"key":"2022100616085110900_CIT0035","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/abbs\/gmy038","article-title":"The inhibitory effect of BKCa channels induced by autoantibodies against angiotensin II type 1 receptor is independent of AT1R","volume":"50","author":"Wang","year":"2018","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"2022100616085110900_CIT0036","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1159\/000494744","article-title":"Angiotensin II type I receptor agonistic autoantibody induces podocyte injury via activation of the TRPC6- calcium\/calcineurin pathway in pre-eclampsia","volume":"43","author":"Yu","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"2022100616085110900_CIT0037","doi-asserted-by":"crossref","DOI":"10.1080\/14656566.2020.1735356","article-title":"An evaluation of the fixed-dose combination sacubitril\/valsartan for the treatment of arterial hypertension","author":"Wehland","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"2022100616085110900_CIT0038","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1681\/ASN.2005050468","article-title":"Genetic variation of the renin-angiotensin system and chronic kidney disease progression in black individuals in the atherosclerosis risk in communities study","volume":"17","author":"Hsu","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2022100616085110900_CIT0039","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/01.HYP.0000088853.27673.D0","article-title":"Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension","volume":"42","author":"Jones","year":"2003","journal-title":"Hypertension"},{"key":"2022100616085110900_CIT0040","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/hr.2010.156","article-title":"Association of the angiotensin II type I receptor gene +1166 A&gt;C polymorphism with hypertension risk: evidence from a meta-analysis of 16474 subjects","volume":"33","author":"Niu","year":"2010","journal-title":"Hypertens Res"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaa071\/33381607\/hpaa071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/33\/8\/734\/46354141\/ajh_33_8_734.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/33\/8\/734\/46354141\/ajh_33_8_734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T17:21:27Z","timestamp":1665076887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/33\/8\/734\/5824812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4,24]]},"published-print":{"date-parts":[[2020,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaa071","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,4,24]]}}}